Call for Abstracts: DIA EuroMeeting 2017

DIA29 - 31 March 2017, Glasgow, UK.
The DIA EuroMeeting 2017 provides a platform for experts from all relevant disciplines within the entire healthcare development and access process to debate and find solutions to some of the most pertinent challenges faced in an ever-evolving healthcare system - including the need to drive innovation.

DIA invites you to submit presentation, session and tutorial abstracts for the 29th Annual EuroMeeting in Glasgow, UK. You may submit more than one abstract. Abstracts should fall under one of the themes detailed bellow.

Session Abstract
A session abstract is a 90-minute session concept delivered lecture-style from the podium. The abstract author is considered the session chair and will coordinate efforts in recruiting speakers and managing the session (including the facilitation of question and answers from the audience). PowerPoint presentations are required. We encourage innovative ideas for session formats that will enhance interaction between stakeholders.

Presentation Abstract
A presentation abstract is for a 20-minute presentation in a specific topic area; the abstract author is considered the speaker. A PowerPoint presentation is required. If selected, the abstract will consist of a single presentation which will fit within a session.

Tutorial Abstract
A tutorial is a 'hands-on', interactive learning experience. A tutorial consists of 3 hours of instruction with a 30-minute break. The abstract author is considered the instructor. One co-instructor may be recruited but cannot be from the same company/organisation as the author.

Hot-Topic / Stand-Alone Sessions
Each year, there are a number of sessions which do not fit directly under the programme themes. If your abstract clearly does not fit with any of the themes / topics outlined, you may submit it for consideration as a hot-topic / stand-alone presentation or session.

How to maximise the probability of your abstract being accepted
Abstracts will be selected by the EuroMeeting Programme Committee. The theme leaders have indicated the strategic topics they would like to address.

  • Focus your abstracts on the proposed topics in this flyer. If your abstract clearly does not fit, submit it as a hot topic / stand-alone presentation or session
  • Your abstract should be as clear and as detailed as possible to enable the theme leaders to make a judgement on its suitability for the programme
  • Abstracts must be non-promotional and non-commercial in order to be considered

If you have any questions about abstract submission, please email the EuroMeeting team: This email address is being protected from spambots. You need JavaScript enabled to view it.

The deadline for submitting abstracts is Monday, 27 June 2016.

For further information, please visit:
http://www.diaglobal.org/en/conference-listing/meetings/2017/03/29th-annual-euromeeting

About DIA
For over 50 years, DIA has served as a global platform for more than 30,000 health care product development professionals, researchers, regulators, clinicians, academics and patient advocates to collaborate to improve health globally through the advancement of lifesaving medicines and technologies. As the premier professional community for the health care product development ecosystem, DIA (the Drug Information Association) provides global players a neutral and transparent forum for the exchange of ideas and collaboration. By offering access to tools, resources, and networking opportunities, DIA provides its members and international participants objective opportunities for extending debate and discussion to advance scientific and medical innovation.

DIA is an independent, global nonprofit organization based in Washington, DC, USA, with regional offices representing the Americas (Horsham, PA, USA); Europe, the Middle East, and Africa (Basel, Switzerland); and Asia (Beijing, China; Mumbai, India; and, Tokyo, Japan).

Most Popular Now

BioMotiv and Bristol-Myers Squibb announce the lau…

BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from ...

CEPI and GSK announce collaboration to strengthen …

CEPI, the Coalition for Epidemic Preparedness Innovations, and GSK announced a new collaboration aimed at helping the global effort to develop a vaccine for the 2019-nCoV...

Sandoz completes acquisition of Aspen's Japanese o…

Sandoz today announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen ...

Sanofi brain-penetrant BTK inhibitor meets primary…

The Sanofi Phase 2b study evaluating its investigational BTK (Bruton's tyrosine kinase) inhibitor (SAR442168), an oral, brain-penetrant, selective small molecule, achieve...

Roche reports very strong results in 2019

In 2019, Group sales rose 9% to CHF 61.5 billion and core EPS grew 13%, ahead of sales. The core operating profit increased 11%, reflecting the strong underlying business...

Merck donates one billionth praziquantel tablet

Merck, a leading science and technology company, today announced that it has already donated 1 billion tablets of praziquantel, the standard medication for the treatment ...

Bayer and Nuvisan create new research unit in Berl…

Bayer AG today announced that it entered into a definitive agreement to transfer a large part of its Berlin-based small molecule research unit to Nuvisan, an internationa...

Novartis announces MET inhibitor capmatinib (INC28…

Novartis announced that the US Food and Drug Administration (FDA) accepted and granted Priority Review to capmatinib’s (INC280) New Drug Application (NDA). Capmatinib is ...

WHO, China leaders discuss next steps in battle ag…

The Director-General of the World Health Organization (WHO), Dr Tedros Adhanom Ghebreyesus, met President Xi Jinping of the People's Republic of China in Beijing. They sh...

FDA approves first drug for treatment of peanut al…

Today the U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, tha...

Can bilingualism protect the brain even with early…

A study by York University psychology researchers provides new evidence that bilingualism can delay symptoms of dementia. Alzheimer's disease is the most common form of d...

Poliovirus therapy shows potential as cancer vacci…

A modified form of poliovirus, pioneered at Duke Cancer Institute as a therapy for glioblastoma brain tumors, appears in laboratory studies to also have applicability for...